PL2054074T3 - Zmodyfikowana erytropoetyna - Google Patents

Zmodyfikowana erytropoetyna

Info

Publication number
PL2054074T3
PL2054074T3 PL07812992T PL07812992T PL2054074T3 PL 2054074 T3 PL2054074 T3 PL 2054074T3 PL 07812992 T PL07812992 T PL 07812992T PL 07812992 T PL07812992 T PL 07812992T PL 2054074 T3 PL2054074 T3 PL 2054074T3
Authority
PL
Poland
Prior art keywords
modified erythropoietin
erythropoietin
modified
Prior art date
Application number
PL07812992T
Other languages
English (en)
Inventor
Abraham Abuchowski
Lihysyng Stanford Lee
Original Assignee
Prolong Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolong Pharmaceuticals Llc filed Critical Prolong Pharmaceuticals Llc
Publication of PL2054074T3 publication Critical patent/PL2054074T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL07812992T 2006-08-04 2007-07-16 Zmodyfikowana erytropoetyna PL2054074T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83542906P 2006-08-04 2006-08-04
PCT/US2007/073629 WO2008019214A1 (en) 2006-08-04 2007-07-16 Modified erythropoietin
EP07812992.1A EP2054074B8 (en) 2006-08-04 2007-07-16 Modified erythropoietin

Publications (1)

Publication Number Publication Date
PL2054074T3 true PL2054074T3 (pl) 2015-03-31

Family

ID=39033318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07812992T PL2054074T3 (pl) 2006-08-04 2007-07-16 Zmodyfikowana erytropoetyna

Country Status (13)

Country Link
US (1) US8765924B2 (pl)
EP (1) EP2054074B8 (pl)
JP (3) JP5723528B2 (pl)
KR (2) KR101304081B1 (pl)
CN (2) CN105820231A (pl)
CA (1) CA2659990C (pl)
DK (1) DK2054074T3 (pl)
ES (1) ES2529234T3 (pl)
IL (2) IL196866A (pl)
PL (1) PL2054074T3 (pl)
PT (1) PT2054074E (pl)
SI (1) SI2054074T1 (pl)
WO (1) WO2008019214A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2054074T3 (pl) * 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
EP2446034A4 (en) * 2009-06-22 2013-11-27 Ipca Lab Ltd NEW POLYNUCLEOTIDE MOLECULES FOR IMPROVED GENE EXPRESSION
BR112012008341A2 (pt) * 2009-09-15 2020-08-25 Kaneka Corporation eritropoietina modificada à qual molécula de cadeia longa solúvel em água é adicionada
CN103044539B (zh) * 2010-04-09 2014-10-22 苏州元基生物技术有限公司 重组促红细胞生成素及制备方法
WO2012122025A2 (en) * 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
CU20140003A7 (es) * 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
KR102268647B1 (ko) * 2017-06-12 2021-06-23 한국코러스 주식회사 안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
CN119080909A (zh) * 2024-08-29 2024-12-06 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
DE3785086T2 (de) 1986-06-04 1993-07-08 Agency Ind Science Techn Zubereitung fuer zellkultur und ihre verwendung.
JP2520681B2 (ja) 1986-08-04 1996-07-31 ザ ユニバーシティ オブ ニュー サウス ウェールズ 生合成のヒトの成長ホルモン製品
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
DE68917642T2 (de) 1988-05-25 1995-02-09 Teijin Ltd Verfahren zur kontinuierlichen Züchtung von haftenden tierischen Zellen.
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU635844B2 (en) 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE4115722A1 (de) 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5994122A (en) 1994-08-31 1999-11-30 Prodevco (Nz) Limited Composter with slanted shelves
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
SI0964702T1 (sl) 1996-08-02 2007-02-28 Ortho Mcneil Pharm Inc Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1311285T4 (en) 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
US20040082765A1 (en) 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
MXPA03005406A (es) 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
ATE505204T1 (de) * 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
WO2003055526A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
US20060239961A1 (en) 2002-02-15 2006-10-26 Nektar Therapeutics Al, Corporation Hydrolytically degradable alkylene oxide based polymers
US7605231B2 (en) * 2002-04-26 2009-10-20 Yasuhiko Tabata Gelatin derivatives and high-molecular micelle comprising the derivatives
AU2003246486A1 (en) 2002-07-19 2004-02-09 Cangene Corporation Pegylated erythropoietic compounds
CA2507904C (en) 2002-12-19 2014-12-02 M. Elizabeth Snell Cyanovirin variant-polymer conjugates
WO2004060406A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
DK2599502T3 (en) 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
WO2004108667A2 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
PT1656410E (pt) 2003-07-22 2010-06-11 Nektar Therapeutics Processo para preparação de polímeros funcionalizados a partir de álcoois poliméricos
US20050214250A1 (en) 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
KR101276422B1 (ko) 2004-03-15 2013-06-19 넥타르 테라퓨틱스 Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트
KR101100059B1 (ko) 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
AU2005275108B2 (en) 2004-07-16 2011-05-12 Nektar Therapeutics Conjugates of a GM-CSF moiety and a polymer
EP1848461A2 (en) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
AU2006278490A1 (en) 2005-08-04 2007-02-15 Nektar Therapeutics Conjugates of a G-CSF moiety and a polymer
JP2009514814A (ja) * 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
PL2054074T3 (pl) * 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
WO2011041376A1 (en) 2009-09-30 2011-04-07 Prolong Pharmaceuticals Modified granulocyte colony stimulating factor (g-csf)

Also Published As

Publication number Publication date
PT2054074E (pt) 2014-11-07
ES2529234T3 (es) 2015-02-18
IL196866A0 (en) 2011-08-01
JP5802644B2 (ja) 2015-10-28
JP5723528B2 (ja) 2015-05-27
JP2009545608A (ja) 2009-12-24
US8765924B2 (en) 2014-07-01
SI2054074T1 (sl) 2014-12-31
JP5961730B2 (ja) 2016-08-02
EP2054074B1 (en) 2014-10-01
DK2054074T3 (da) 2014-11-03
US20100184655A1 (en) 2010-07-22
KR101304081B1 (ko) 2013-09-05
IL196866A (en) 2016-08-31
JP2015231996A (ja) 2015-12-24
CA2659990A1 (en) 2008-02-14
CA2659990C (en) 2016-03-22
CN101534847A (zh) 2009-09-16
HK1131542A1 (en) 2010-01-29
EP2054074A1 (en) 2009-05-06
IL232923A0 (en) 2014-07-31
EP2054074B8 (en) 2014-11-12
WO2008019214A1 (en) 2008-02-14
CN105820231A (zh) 2016-08-03
JP2013079258A (ja) 2013-05-02
KR20120105494A (ko) 2012-09-25
EP2054074A4 (en) 2009-12-23
IL232923A (en) 2016-08-31
KR20090046923A (ko) 2009-05-11

Similar Documents

Publication Publication Date Title
DE602007002700D1 (en) Interventionsfreies frac-system
DE602007008085D1 (en) Dihydropyrazolopyrimidinonderivate
DE602007001601D1 (en) Glasuntersuchung
ZA200709091B (en) Erythropoietin variants
IL232923A0 (en) Enhanced erythropoietin
DE602007006989D1 (en) Spiropiperidinderivate
EP2084019A4 (en) PAINT SCRAPER
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
DE602007011622D1 (en) Penem-prodrugs
DK1989111T3 (en) Satellitluftbremseapparat
DE502007001126D1 (en) Eiten
GB0625861D0 (en) Modified flexicast/flexisplint
GB0602258D0 (en) Privyphone
GB0601584D0 (en) Cosyhold headscarf
GB0715126D0 (en) Erythropoietin
AU3514P (en) ARCBENT Arctotis fastuosa
AU4914P (en) CalflatGL Calothamnus quadrifidus
GB0624909D0 (en) Modified Drinklid
GB0604310D0 (en) Corcost one
GB0600152D0 (en) Cup-1
GB0601358D0 (en) Boot-buddy
GB0600180D0 (en) Infofob
GB0611276D0 (en) Scrush
GB0602152D0 (en) Babydrape
GB0600063D0 (en) Unicon